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Background: The relationships between lncRNAs and tumors have currently become one of the focuses on cancer
studies. However, there are a few studies about lncRNAs in non-small cell lung cancer (NSCLC) at present.
Methods: Microarray analysis was designed to study the expression patterns of lncRNAs in three pairs of NSCLC
tissues. The expression of lncRNA RGMB-AS1 and repulsive guidance molecule b (RGMB) were detected in 72 paired
NSCLC tissues and adjacent normal tissues by qRT-PCR assay. The relations of lncRNA RGMB-AS1 and RGMB expression
with clinicopathological factors of NSCLC patients were explored. A549 and SPC-A-1 cells were transfected with siRNA
of lncRNA RGMB-AS1 and negative control. RGMB expression level was detected by qRT-PCR assay and western
blot analysis.
Results: The results of microarray found that 571 lncRNAs were differentially expressed in NSCLC tissues (Fold
change cut-off: 5.0, P < 0.05), including 304 upregulated and 267 downregulated lncRNAs. The results of qRT-PCR
showed that lncRNA RGMB-AS1 expression was significantly higher in NSCLC tissues than in adjacent normal tissues
(P < 0.05), while RGMB mRNA showed an opposite trend (P < 0.05). Correlation analysis indicated that the expression of
lncRNA RGMB-AS1and RGMB mRNA were inversely correlated (R2 = 0.590, P < 0.05). While lncRNA RGMB-AS1 and
RGMB expression levels in NSCLC tissues were associated with the occurrence of differentiation status, lymph
node metastases and TNM stage (P < 0.05). Transfection with siRNA of lncRNA RGMB-AS1, subsequent results
showed that RGMB mRNA and protein expression were upregulated (P < 0.05) in A549 and SPC-A-1 cells compared
to the control groups.
Conclusion: We identified lncRNA RGMB-AS1 was upregulated and RGMB was downregulated in NSCLC patients. Both
were related to differentiation status, lymph node metastases and TNM stage. Studies also indicated that lncRNA
RGMB-AS1and RGMB were inversely correlated.
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Lung cancer, one of the most frequent malignancies in the
world, is rapidly becoming the main cause of cancer related
death nowadays [1]. Approximately 85 % of patients are
diagnosed with non-small cell lung cancer (NSCLC). Modi-
fications of chemotherapy combinations, the addition of
monoclonal antibodies, including bevacizumab [2, 3] and
cetuximab [4, 5], and the incorporation of histologic subtype
[6] into treatment decisions have added to the survival of
patients with advanced NSCLC. Unfortunately, therapeutic
outcomes appear to have reached a plateau, with response
rates of 20 to 35 % and median survival of 8 to 12 months
[7]. Currently, encouraging new targeted agents have led to
a better understanding of the molecular pathogenesis that
causes NSCLC, especially the non-protein-coding portion
(~90 %) as non-coding RNA (ncRNA) of the genome [8].
The ncRNAs characterize as three types, long ncRNAs,
mid-size ncRNAs and short ncRNAs [9]. Although most
studies on ncRNAs are focused on short ncRNAs, such as
microRNAs (miRNAs) [10], long non-coding RNAs
(lncRNAs) are rapidly gaining prominence recently.
LncRNAs, tentatively defined as non-coding RNAs more
than 200 nucleotides (nt) [11], are usually divided into ex-
onic lncRNAs, intronic lncRNAs, intergenic lncRNAs and
overlapping lncRNAs in accordance with their location
relative to the protein-coding transcripts [12]. In recent
years, a large number of lncRNAs have been identified
and the abnormal expression of lncRNAs has been impli-
cated in imprinting [13], enhancing various biological
functions [14], X chromosome inactivation, charomatin
structure [15]. Thus, lncRNAs are critical for normal de-
velopment and, in many cases, are deregulated in diseases,
such as cancer [16–19].
Currently, studies on lncRNAs in NSCLC are limited. In
this study, we analyzed the expression patterns of lncRNAs
in three pairs of NSCLC tissues. With performing qRT-
PCR assay, we chose some kinds of lncRNAs to test and
verify the results of microarray analysis. Combined with the
UCSC data-base and bioinformatics analysis, not all
lncRNAs from microarray showed potential significance.
With the screening tests, we found lncRNA RGMB-AS1
may have potential function in the development of NSCLC.
So we focused on the expression of lncRNA RGMB-AS1,
and analyzed expression of its potential protein on the base
of their location. Then the relationships between the ex-
pression of lncRNA RGMB-AS1 and repulsive guidance
molecule b (RGMB) and clinicopathological factors of pa-
tients with NSCLC were explored. Our results may provide
a new perspective for the mechanisms of NSCLC.
Methods
Patients and tissue samples
This study was approved by the Ethics Committee of
Zhengzhou University. Seventy-two paired NSCLC tissuesand adjacent normal tissues (≥3 cm away from tumor)
were obtained from patients who received surgical re-
section of NSCLC between 2012 and 2014 in the First
Affiliated Hospital of Zhengzhou University. Of the
seventy-two pairs of samples, three were used in
lncRNA microarray analysis and all pairs were used for
additional evaluations. Patients were diagnosed with
NSCLC was confirmed by histopathology. The tumor
samples and matched adjacent normal tissues were
snap-frozen in liquid nitrogen immediately after resec-
tion until total RNA extraction.
Cell culture and transfection
Human NSCLC cell lines (A549 and SPC-A-1) were ob-
tained from the Type Culture Collection of the Chinese
Academy of Sciences (Shanghai, China). Both were cul-
tured in RPMI-1640 medium (Gibco BRL, Grand Island,
NY) supplemented with 10 % fetal bovine serum, 100 U/
mL penicillin, and 100 μg/mL streptomycin at 37 °C in a
humidified 5 % CO2 atmosphere. In all experiments, ex-
ponentially growing cells were used.
For transfection, cells were seeded into six-well plates at
a density of 5 × 104 cells/well. When cells viability reached
approximately 80 %, transient transfection was performed
using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA,
USA) following the manufacturer’s instructions. siRNA,
working on lncRNA RGMB-AS1, and control oligonucleo-
tide (negative control) were synthesized by Shanghai Gene-
Pharma Co. Ltd.
RNA extraction
For NSCLC tissues, if the proportion of NSCLC cells in
a tissue section was >80 % then the frozen block was
subjected to RNA extraction. According to the manufac-
turer's protocol, total RNA was extracted from 72 pairs
of snap-frozen NSCLC tissues and adjacent normal tis-
sues using TRIzol reagent (Invitrogen, CA, USA). For
NSCLC cell lines, total RNA was extracted with an RNA
Extraction Kit (Qiagen). The integrity of the RNA was
evaluated by a Nanodrop ND-1000 (Thermo Scientific,
Worcester, USA). The value of OD260/280 is around 1.8
as a criterion of acceptable purity.
Microarray analysis
Of the seventy-two pairs of samples, three pairs of
matched samples were used for microarray analysis.
RNA was purified from total RNA after removal of
rRNA (mRNA-ONLY™ Eukaryotic mRNA Isolation Kit,
Epicentre). Then, each sample was transcribed into
fluorescent cRNA along the entire length of the tran-
scripts without 3’ bias utilizing a random priming
method. The labeled cRNAs were hybridized onto the
Human lncRNA Array v2.0 (8 × 60 K, Arraystar).
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For qRT-PCR assay, RNA was reverse transcribed to cDNA
from 1.0 μg of total RNA using a Reverse Transcription Kit
(Thermo Scientific),. Real-time PCR analyses were con-
ducted using the Power SYBR Green (Thermo Scientific).
All protocols were carried out according to the manufactur-
er's instructions. LncRNA RGMB-AS1 (NR_033932) and
RGMB mRNA (NM_001012761) expression were deter-
mined by qRT-PCR. GAPDH mRNA (NM_002046) served
as an endogenous control for normalization. The correlat-
ing primers are the following sequences: lncRNA RGMB-
AS1, forward: 5’AGTGGGCAAACTTCAACGTTC 3’, and
reverse: 5’ GAGCTGCCATTGAATTAATCCG 3’. RGMB,
forward: 5’TTCAGGTTCAAGTGA CAAACG-3’ and re-
verse: 5’-ACTGAACCTGACCGTACATCATCTGTCACA
GCT TGGTA -3’. GAPDH, forward: 5’-AGAGGCAGGGA
TGATGTTCTG-3’, and reverse: 5’-GACTCATGACCACA
GTCCATGC-3’. The PCR reaction was executed on an
ABI 7500 Fast Real-Time PCR System (Applied Biosystems,
CA, USA) at 95 °C for 180 s, followed by 40 cycles of 95 °C
for 15 s and 65 °C for 30 s. All experiments were performed
in triplicate, and melting curve analysis was performed to
ensure the specificity of the products after amplification.
The median in each triplicate was used to calculate
relative LncRNA RGMB-AS1 and RGMB mRNA con-
centrations (ΔCt = Ct median lncRNA or mRNA - Ct
median GAPDH), which was then converted to x-fold
changes(2-ΔCt) [20].Table 1 Part of lncRNAs detected using microarray in three
NSCLC patients





LOC145757 4.1850148 ANKRD20A5P −2.416844
DLX6-AS1 3.893559 C22orf34 −2.4658422
LOC284801 3.6185247 MAGI2-AS3 −2.565988
KIAA1908 3.4127824 LOC100505495 −3.384433
XLOC_008466 3.2270826 MGC27382 −4.104419Western blot analysis
Total proteins were extracted from the transfected cells
at 48 h after transfection and then were subjected to
SDS-PAGE (SDS/polyacrylamide (10 %) gel electrophor-
esis) and transferred electrophoretically onto polyvinyli-
dene difluoride (PVDF) filter membranes (Whatman).
The membranes were blocked in 5 % skim milk for 1 h,
washed four times with Tris-buffered saline containing
Tween 20 (TBST) at room temperature, then incubated
overnight at 4 °C with diluted primary antibody (rabbit
anti-human RGMB antibody, 1:500, Santa Cruz Biotech-
nology). Following extensive washing with TBST, the
membranes were incubated with secondary antibody
(goat anti-rabbit IgG, 1:2000, Santa Cruz Biotechnology)
for 1 h. After four washes (15 min each) with TBST at
room temperature, the immunoreactivity was visualized
by enhanced chemiluminescence. The antibody against
GAPDH (Santa Cruz Biotechnology) served as an en-
dogenous reference.PRSS30P 3.149014 LOC400550 −4.5237017
LINC00665 2.945509 XLOC_001412 −4.6995843
RGMB-AS1 2.6495147 XLOC_l2_006399 −4.907096
HOTAIR 2.581743 RP11-165H20.1 −5.3639335
T: NSCLC tissues; N: adjacent normal tissuesStatistical analysis
SPSS17.0 soft-ware (SPSS, Inc, Chicago, IL) was per-
formed for statistical analysis. Data were expressed as the
mean ± the standard deviation (SD). The student’s t-testand a one-way analysis of variance (ANOVA) were used in
the comparison of means from different samples. P values
of less than 0.05 were considered statistically significant.Results
Overview of different lncRNA expression profilings in
NSCLC tissues relative to adjacent normal tissues
We profiled lncRNAs expression in tumors from NSCLC
patients. Comparing to adjacent normal tissues on the basis
of lncRNA array results, we found that 571 lncRNAs were
differentially expressed in NSCLC tissues (Fold change cut-
off: 5.0, P < 0.05), including 304 upregulated and 267
downregulated lncRNAs. Table 1 showed 14 lncRNAs
randomly selected among the differential lncRNAs
(Log2 fold change, P < 0.05).
Expression of lncRNA RGMB-AS1 and RGMB mRNA in
NSCLC tissues
In 72 NSCLC tissues, we performed qRT-PCR to check
lncRNA RGMB-AS1 and RGMB mRNA expression,
and found that lncRNA RGMB-AS1 expression was sig-
nificantly higher in NSCLC tissues than in adjacent
normal tissues (P < 0.05, Fig. 1a), while RGMB mRNA
showed an opposite trend (P < 0.05, Fig. 1b). These data
indicated that the expression of lncRNA RGMB-AS1
and RGMB mRNA were inversely correlated (R2 = 0.590,
P < 0.05, Fig. 1c).
Association of lncRNA RGMB-AS1 and RGMB expression
with clinicopathologic features of NSCLC patients
Using the qRT–PCR analysis and with adjacent normal
tissues as reference, the clinicopathologic features of the
72 NSCLC samples included in this study are presented in
Table 2. We found that lncRNA RGMB-AS1 and RGMB
expression levels in NSCLC tissues were associated with
the occurrence of differentiation status, lymph node
Fig. 1 Expressions of lncRNA RGMB-AS1 and RGMB mRNA in NSCLC tissues and adjacent normal tissues. a Relative expression of lncRNA RGMB-AS1 in
paired NSCLC tissues (tumor group) and adjacent normal tissues(non-tumor group). There is a statistically significant difference (P < 0.05). b RGMB
mRNA expression in the tumor group was notably higher than in non-tumor group (P < 0.05). c The expressions of lncRNA RGMB-AS1 and RGMB
mRNA were inversely correlated (R2 = 0.590, P < 0.05)
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significant differences were observed between lncRNA
RGMB-AS1, RGMB expression and either gender or age
(P >0.05; Table 2).
siRNA of lncRNA RGMB-AS1 can promote the expression
of RGMB in A549 and SPC-A-1 cells
To further study that lncRNA RGMB-AS1 expression
has an opposite correlation with RGMB expression, we
studied whether knockdown of lncRNA RGMB-AS1
would have an effect on the expression of RGMB.Table 2 Association of lncRNA RGMB-AS1 and RGMB expression wit
Clinicopathological factor n LncRNA RGMB-AS1 expre
Median ± SD
Gender
Male 47 0.0734 ± 0.0641
Female 25 0.0763 ± 0.0557
Age(years)
≥60 28 0.0634 ± 0.0638
<60 44 0.0814 ± 0.0587
Histology
SCC 44 0.0718 ± 0.0584
Adeno 28 00784 ± 0.0656
Differentiation
Well 16 0.0269 ± 0.0323
Moderate 39 0.0556 ± 0.0378
Poor 17 0.1622 ± 0.0281
Lymphnode metastasis
Positive 37 0.1146 ± 0.0514
Negative 35 0.0319 ± 0.0367
TNM
I + II 31 0.0265 ± 0.0326
III + IV 41 0.1106 ± 0.0517
SCC: Squamous cell carcinoma; Adeno: Adenocarcinoma
*Indicated statistical significance (P < 0.05)Transfection with siRNA of lncRNA RGMB-AS1, subse-
quent qRT-PCR and western blot analysis indeed
showed that RGMB mRNA (P < 0.05, Fig. 3a) and pro-
tein expression (P < 0.05, Fig. 3b) were upregulated in
A549 and SPC-A-1 cells compared to the control groups.
Discussion
The relationship between lncRNAs and tumors has
currently become one of the focuses of cancer studies.
In digestive system tumors, lncRNA HNF1A-AS1 has
been shown to regulate proliferation and migration inh clinicopathologic features of NSCLC patients
ssion(2–ΔCt) RGMB mRNA expression(2–ΔCt)
P Media ± SD P
0.847 0.4148 ± 0.2016 0.301
0.3656 ± 0.1684
0.226 0.4320 ± 0.2111 0.227
0.3759 ± 0.1761
0.662 0.4020 ± 0.1989 0.812
0.3909 ± 0.1813
0.007* 0.5292 ± 0.1771 0.032*
0.4299 ± 0.1633
0.2000 ± 0.0883
0.000* 0.3169 ± 0.1640 0.000*
0.4832 ± 0.1819
0.000* 0.5068 ± 0.1751 0.007*
0.3152 ± 0.1598
Fig. 2 The correlation of lncRNA RGMB-AS1 and RGMB mRNA expression levels in NSCLC tissues. a, b: In poor differentiation tumor tissues, the
expression levels of lncRNA RGMB-AS1 were significantly higher while RGMB mRNA were lower than in well and moderate differentiation tissues
(P < 0.05). c, d: NSCLC tissues were divided into two groups of metastasis-positive and metastasis-negative. The high expression of lncRNA RGMB-AS1
and low expression of RGMB mRNA were notably associated with lymph node metastasis (P < 0.05). e, f: Significant differences were observed in
lncRNA RGMB-AS1 and RGMB mRNA expression in different TNM stages (P < 0.05). P < 0.05 compared with the control group
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was found overexpression in human hepatocellular carcin-
omas (HCC) [22]. The highly upregulated in liver cancer
(HULC) gene expression is confined to colorectal carcin-
omas that metastasize to the liver [23]. In hematological
system tumors, lncRNA NEAT1 expression has beenrevealed to impair myeloid differentiation in acute pro-
myelocytic leukemia cells [24]. In urinary system tu-
mors, there have been reports in recent years about
lncRNA H19 associating with bladder cancer [25, 26].
In the male reproductive system, prostate cancer gene
expression marker 1 (PCGEM1) has been demonstrated as
Fig. 3 siRNA of lncRNA RGMB-AS1 promoted the expression of
RGMB in A549 and SPC-A-1 cells. a Cells were transfected with siRNA
of lncRNA RGMB-AS1 and NC. RGMB mRNA level was detected by
qRT-PCR assay. RGMB mRNA expression was upregulated in A549
and SPC-A-1 cells after transfection with siRNA of lncRNA RGMB-AS1
and NC respectively (*P < 0.05). b, RGMB protein level was detected
by Western blot assay. GAPDH protein was regarded as endogenous
normalize. The expression level was also upregulated (*P < 0.05).
siRNA: cells transfected with siRNA of lncRNA RGMB-AS1; NC: cells
transfected with unrelated siRNA as negative control; Blank:
non-transfected cells. *P < 0.05 compared with the control group
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noncoding RNA (ncRNA) gene [27]. In respiratory system
tumors, MALAT1 was originally identified as a prognostic
marker for metastasis and patient survival in NSCLC,
specifically in early stages of lung adenocarcinoma [28].
In this study, we have identified lncRNA RGMB-AS1 is
aberrantly expressed in human NSCLC tissues com-
pared to paired adjacent normal tissues. We also found
that altered lncRNA RGMB-AS1 expression levels are
associated with the occurrence of lymph node metasta-
ses, and the differentiation status and TNM stage in
NSCLC patients, which may be a hint for NSCLC oc-
currence and be a potential biomarker for the diagnosis
of early NSCLC.
Simultaneously, we also identified RGMB is downregu-
lated in human NSCLC tissues via qRT-PCR analysis.
Statistical analysis showed RGMB expression was also
related to the occurrence of lymph node metastases, and
the differentiation status and TNM stage in NSCLC pa-
tients. RGMB, also known as DRAGON, is a member of
the repulsive guidance molecules (RGMs) family which
consists of RGMA, RGMB, and RGMC [29]. RGMs are
a group of cysteine rich 33 kDa proteins, including an N-
terminal signal peptide, proteolytic cleavage site, partial
von Willebrand factor type D domain, and glycophospha-
tidylinositol (GPI) anchor [30, 31]. RGM proteins canfunction as bone morphogenetic protein (BMP) corecep-
tors [32–34], which are members of the transforming
growth factor beta (TGF-β) family of ligands and play a
role in many biological activities. Specifically, RGMB dir-
ectly interacts with BMP receptors for BMP-2 and BMP-4
enhancing binding to their ligands [35]. RGMs work
as BMP co-receptors and by participating in BMP sig-
nalling pathway may also be involved in cancer develop-
ment and progression. In prostate cancer, the knockdown
of RGMB significantly enhanced the prostate cancer cell
capacity, namely increased growth, adhesive, motility and
mobility [36]. Knockdown of RGMB also was studied in
breast cancer. The results showed the promotion of
growth, survival, adhesion, and migration of breast cancer
cells [37, 38].
The UCSC data-base results showed that lncRNA
RGMB-AS1 was localized in human chromosome 5 be-
tween 98105322 and 98108829 base sites. To check the lo-
cation of RGMB, UCSC data-base also showed that it was
localized in human chromosome 5 between 98109606
and 98129556 base sites. The locations of both lead us
to infer that lncRNA RGMB-AS1 and RGMB may have
a certain expression control. Applying statistical ana-
lysis and performing RNA interference technique in
A549 and SPC-A-1 cells, we revealed that lncRNA
RGMB-AS1 expression was inversely associated with
RGMB expression. The detailed molecular analysis of
lncRNA RGMB-AS1 and RGMB still need to be further
studied.Conclusions
In summary, we identified upregulation of lncRNA RGMB-
AS1 and downregulation of RGMB in 72 NSCLC pa-
tients, and both were related to differentiation status,
lymph node metastases and TNM stage. We also pro-
vided evidence demonstrating the probable association
between lncRNA RGMB-AS1 and RGMB. Based on
these findings, we propose that lncRNA RGMB-AS1
and RGMB may serve as a new direction in NSCLC re-
search. But more elaborate studies will be necessary for
further exploration of the potential role of lncRNA
RGMB-AS1 and RGMB in development of NSCLC in
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